Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [5][4]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to a range of $1.840 billion to $1.854 billion from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations. The company also projected a net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 to $73.89 [6].

Core Viewpoint - The Ardent Health class action lawsuit alleges that the company and its executives made misleading statements regarding financial practices and liability reserves, leading to significant financial losses for investors during the specified class period [1][3]. Company Overview - Ardent Health, Inc. operates a network of hospitals and clinics providing various healthcare services [2]. Allegations of the Lawsuit - The lawsuit claims that Ardent Health did not rely on accurate methods for determining the collectability of accounts receivable, which allowed the company to report inflated financial figures [3]. - It is alleged that Ardent Health's accounts receivable framework utilized a "180-day cliff" for reserving accounts, delaying the recognition of losses on uncollectible accounts [3]. - The company reportedly lacked sufficient professional malpractice liability insurance and reserves to cover claims, particularly in light of increasing social inflationary pressures in the New Mexico market [3]. Financial Impact - On November 12, 2025, Ardent Health disclosed a $43 million decrease in third quarter 2025 revenue due to revised accounts receivable collectability assessments and a new revenue accounting system [4]. - The company also cut its 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million - $615 million to $530 million - $555 million, citing persistent industry-wide cost pressures [4]. - Additionally, a $54 million increase in professional liability reserves was recorded due to recent settlements and ongoing litigation, reflecting broader industry trends [4]. - Following these announcements, Ardent Health's stock price fell nearly 34% [4]. Legal Process - Investors who purchased Ardent Health securities during the class period can seek to be appointed as lead plaintiff in the lawsuit, representing the interests of the class [5]. - The lead plaintiff has the authority to select a law firm for litigation and does not need to be the lead plaintiff to share in any potential recovery [5]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6]. - The firm has a strong track record in obtaining significant recoveries in securities class action cases, including the largest recovery in history [6].

Core Viewpoint - A securities class action lawsuit has been filed against Sprouts Farmers Market, Inc. for allegedly misleading investors regarding the company's growth and stability during a period of macroeconomic instability [1][2]. Group 1: Allegations Against Sprouts - The lawsuit claims that Sprouts made false and misleading statements about its growth and stability, which did not align with the actual economic conditions [2]. - It is alleged that Sprouts' consumer base was not as resilient as claimed, leading to reduced spending [2]. - The company reportedly overstated its ability to meet growth projections, which ultimately did not materialize [2]. Group 2: Legal Process and Participation - Investors who suffered losses can seek to be appointed as lead plaintiffs by January 26, 2026, or remain absent class members [3]. - The lead plaintiff will represent the interests of all class members and select legal counsel for the case [3]. Group 3: Law Firm Background - Kessler Topaz Meltzer & Check, LLP is a prominent law firm specializing in securities-fraud class actions and has a history of significant recoveries in securities litigation [4]. - The firm has received multiple accolades for its work in plaintiff-side law, indicating a strong reputation in the legal community [4].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is filed in the U.S. District Court for the Middle District of Tennessee, captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022 [3]. - Investors have until March 9, 2026, to request to lead the case, with claims asserted under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Allegations Against Ardent Health - The lawsuit alleges that Ardent Health misrepresented its process for determining the collectability of accounts receivable, claiming reliance on "detailed reviews of historical collections" while actually using a "180-day cliff" method [4]. - This misrepresentation allowed Ardent Health to report inflated accounts receivable and delay recognizing losses on uncollectable accounts, constituting a violation of federal securities laws [4]. Group 3: Stock Price Impact - On November 12, 2025, Ardent Health announced a $43 million revenue decrease for the quarter and a $54 million increase in professional liability reserves, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5].

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Varonis Systems, Inc. ("Varonis†or the "Company†) (NASDAQ: VRNS) common stock between February 4, 2025 and October 28, 2025, inclusive (the "Class Period†). Varonis investors have until March 9, 2026 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN VARONIS SYSTEMS, INC. (VRNS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO ...

Philadelphia, Pennsylvania--(Newsfile Corp. - January 8, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye" or the "Company") on behalf of investors who purchased or otherwise acquired Skye securities during the period of November 4, 2024 through October 3, 2025 (the "Class Period"), inclusive.Investor Deadline: Investors who purchased Skye securities during the Class Period may, no later than Ja ...

Core Viewpoint - A class action lawsuit has been filed against Jayud Global Logistics Limited for alleged fraudulent activities that led to significant stock price manipulation and investor losses during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Jayud securities from April 21, 2023, to April 30, 2025 [1][2]. - The complaint claims that Jayud's stock price surged from approximately $1.00 to $8.00 per share in early April 2025 without any fundamental news, indicating potential manipulation [3]. - It is alleged that the stock price spike was driven by a fraudulent promotion campaign, including social media influence and impersonation of financial professionals, along with insider selling [3]. Group 2: Stock Performance and Impact - On April 2, 2025, Jayud's stock experienced a dramatic collapse of about 95%, resulting in substantial losses for investors [3]. - The lawsuit highlights the timing of the stock price increase and subsequent collapse as critical events that affected investor confidence and financial outcomes [3]. Group 3: Legal Representation - Investors who purchased Jayud securities during the Class Period have until January 20, 2026, to seek appointment as lead plaintiff representatives [2][4]. - Berger Montague, the law firm handling the case, specializes in complex civil litigation and has a strong track record in class actions [5].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for allegedly misleading investors regarding its operations and financial performance during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Stride securities from October 22, 2024, to October 28, 2025 [1][2]. - Allegations include inflated enrollment numbers, staffing cuts below statutory limits, non-compliance with requirements, and concealment of enrollment losses [3]. Group 2: Impact on Share Price - The truth about Stride's operations was revealed on September 14, 2025, when a school district sued the company for fraud and deceptive practices [4]. - On October 28, 2025, Stride announced that "poor customer experience" led to higher withdrawal rates and fewer enrollments, causing a significant decline in share price [4].

Core Viewpoint - A class action lawsuit has been filed against Charming Medical Ltd. and certain officers for alleged violations of federal securities laws during the Class Period from October 10, 2025, to November 12, 2026 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Charming securities during the specified Class Period [2]. - Allegations include failure to disclose a fraudulent stock promotion scheme, insider trading activities, and misleading public statements regarding the company's business and operations [3]. Group 2: Next Steps for Investors - Investors wishing to join the lawsuit must request to be appointed as lead plaintiff by February 17, 2026, although participation in any recovery does not require this role [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only collect fees if the lawsuit is successful [5]. - The firm has a strong track record, having recovered hundreds of millions of dollars for investors in similar cases [6].

Philadelphia, Pennsylvania--(Newsfile Corp. - January 8, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period").Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than January 9, 2026, seek to be ...